How should kidney function be monitored during Mobocertinib therapy?

ECG/QTc at baseline and periodically (and after electrolyte shifts); Serum electrolytes (especially magnesium and potassium); Renal function during diarrheal episodes; Stool frequency.

How can kidney injury from Mobocertinib be prevented?

Pre-emptive antidiarrheal plan: early loperamide at the first loose stool, dietary measures Aggressive hydration with potassium/magnesium repletion Correct electrolytes and avoid concomitant QT-prolonging agents Hold/dose-reduce for grade >=3 or persistent diarrhea

Who is at higher risk of kidney injury from Mobocertinib?

Baseline CKD and older age; Concurrent diuretics, RAAS blockers or NSAIDs; Inadequate antidiarrheal prophylaxis and baseline electrolyte abnormalities; Concomitant QT-prolonging drugs, hypokalemia or hypomagnesemia.

Back to explorer

Printable monograph

EGFR exon20 TKI

Mobocertinib

Exkivity · MOBO

EGFR exon20 TKI · approved 2021 · 7 citations

Up to date· through 2025

Fairly sourced5/9 · 5 signals

Met: 7 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 4y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2025
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

An EGFR exon-20 TKI whose kidney injury is GI-mediated — torrential diarrhea drives prerenal AKI, watched alongside QT.

MildEGFR exon-20 TKI

Metastatic non-small-cell lung cancer with EGFR exon 20 insertion mutations, after platinum-based chemotherapy (withdrawn 2023)

§01

Signature kidney injury

Signature lesion

Prerenal / Hemodynamic AKI

Representative grade ≥3 incidence6%

Diarrhea is near-universal: any-grade ~83% (up to ~93% pooled), grade >=3 ~20-21%, with median onset ~5 days. AKI is predominantly prerenal; a real-world cohort reported grade >=3 renal failure in ~6%. Precise drug-attributable AKI and QT rates are not robustly quantified beyond class warnings. Reported rate: grade >=3 renal failure in 6% — 16 patients with EGFR exon 20 insertion-mutated NSCLC receiving mobocertinib 160 mg once daily as monotherapy under… (Kian 2022, PMID 36203432).Source: Riely et al., Cancer Discov 2021 (83% any-grade diarrhea); Kian et al., Front Oncol 2022 (real-world grade ≥3 renal failure ~6%, n=16)

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Prerenal AKI follows early diarrhea (within the first week).

Distilled from: “Diarrhea early (within the first week); AKI follows. Prerenal AKI is typically reversible with early volume repletion and diarrhea control.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Acute Tubular NecrosisSecondaryqualitative — no citable incidence
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

6%grade ≥3 incidence

SeverityMild

ReversibilityReversible

Evidence7 citations

Nephron map

Vasculature / Endothelium

Proximal Tubule

Distal Tubule / Collecting Duct

Prerenal / Hemodynamic AKI

Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

Predominantly indirect/prerenal. Severe secretory diarrhea (on-target EGFR inhibition of intestinal epithelium) causes fluid and electrolyte losses, hypovolemia and reduced renal perfusion, producing prerenal AKI that can progress to ischemic ATN if prolonged. Separately, off-target hERG/IKr block (IC50 ~5 microM) plus Cav1.2 inhibition prolongs QTc — relevant to the kidney because diarrhea-driven hypokalemia/hypomagnesemia worsens QT.

Clinical presentation

Early, frequent diarrhea (median onset ~5 days, each episode resolving in ~2 days) with a rising creatinine, low urine output and hypokalemia/hypomagnesemia; QTc prolongation is a recognized label warning.

Management

For diarrhea/AKI: loperamide, restore volume, hold nephrotoxins, and treat the diarrhea driver. For QT: monitor and correct potassium and magnesium, perform ECG monitoring, and hold for significant QTc prolongation. Dose reductions reduce duration of response — balance toxicity against efficacy.Lesion-level management framework

Risk factors

Baseline CKD and older age
Concurrent diuretics, RAAS blockers or NSAIDs
Inadequate antidiarrheal prophylaxis and baseline electrolyte abnormalities
Concomitant QT-prolonging drugs, hypokalemia or hypomagnesemia

Prevention

Pre-emptive antidiarrheal plan: early loperamide at the first loose stool, dietary measures
Aggressive hydration with potassium/magnesium repletion
Correct electrolytes and avoid concomitant QT-prolonging agents
Hold/dose-reduce for grade >=3 or persistent diarrhea

Anticancer mechanism· how it treats cancer

Oral, irreversible (covalent acrylamide-warhead) EGFR tyrosine kinase inhibitor selective for in-frame EGFR exon 20 insertion mutations; structurally derived from osimertinib with a modification conferring exon-20-insertion selectivity.

Note · Voluntarily withdrawn worldwide in 2023 after the confirmatory EXCLAIM-2 trial missed its primary endpoint; entry is of historical/teaching value. The renal mechanism is GI-driven prerenal AKI.

§04

Clinical depth

Renal dose adjustment

Standard 160 mg PO daily. No fully established renal dose-adjustment scheme; renal management is mainly diarrhea/volume control plus dose interruption/reduction.

Dialyzability & ESKD dosing

Not characterized; a small-molecule TKI that is highly protein-bound and hepatically metabolized, so it is unlikely to be dialyzable.

Differential diagnosis

Prerenal/volume-depletion AKI from diarrhea (most likely) versus ischemic ATN, other nephrotoxins/contrast, sepsis, obstructive/tumor-related AKI and other drug-induced AKI.

Monitoring

ECG/QTc at baseline and periodically (and after electrolyte shifts)
Serum electrolytes (especially magnesium and potassium)
Renal function during diarrheal episodes
Stool frequency

Key trials & series

Phase 1/2 (PPP + EXCLAIM; Zhou, JAMA Oncol 2021) — registrational data supporting 2021 accelerated approval
EXCLAIM-2 phase 3 (Janne, J Clin Oncol 2025) — first-line vs platinum; failed, leading to withdrawal

Clinical pearls

Kidney injury is GI-mediated — mostly prerenal from torrential diarrhea, not direct tubulotoxicity; fix the gut and volume and the kidney recovers.
Diarrhea is near-universal (~83-93%) and fast (median ~5 days) — a pre-emptive loperamide plus hydration/electrolyte plan from day 1 is essential.
Watch the potassium/magnesium-QTc loop: diarrhea-induced hypokalemia/hypomagnesemia compounds intrinsic hERG-mediated QT prolongation.
Historical caveat: withdrawn in 2023 after EXCLAIM-2 failed — a cautionary example of an unconfirmed accelerated approval.

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the EGFR exon20 TKI class.

Dermatologic

Rash, HFS, SJS/TEN, vitiligo

Acneiform rash, paronychia

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

Diarrhea

Pulmonary

Pneumonitis, ILD, effusions, hypertension

Interstitial lung disease (EGFR TKIs)

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2021–2025 · 3 since 2023

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Mobocertinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Afatinib

Gilotrif · EGFR TKI

Profile

Diarrhea-driven prerenal AKI.

PREATNLYTE

Mild#1 · 86% phenotype match

Lifileucel

Amtagvi · Tumor-infiltrating lymphocyte (TIL) therapy

Profile

2024 cellular therapy; high-dose IL-2 conditioning → capillary leak AKI.

PREATNLYTE

Moderate#2 · 83% phenotype match

Avapritinib

Ayvakit · KIT / PDGFRA inhibitor

Profile

Edema, intracranial bleeding and cognitive effects.

PRELYTE

Mild#3 · 73% phenotype match

Quizartinib

Vanflyta · FLT3 inhibitor

Profile

2023 AML FLT3 inhibitor; tumor lysis and QT.

PRELYTE

Mild#4 · 73% phenotype match

Imetelstat

Rytelo · Telomerase inhibitor

Profile

2024 MDS agent; tumor lysis risk.

PRELYTE

Mild#5 · 73% phenotype match

Zanidatamab

Ziihera · HER2 bispecific antibody

Profile

2024 biliary-tract HER2 bispecific; renal data emerging.

PRELYTE

Mild#6 · 73% phenotype match

Compare Mobocertinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across EGFR / HER2 inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.